Skip to main content

Eledon Pharmaceuticals, Inc.

ELDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001404281

No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Eledon Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Eledon Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Eledon Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Gros David-Alexandre CChief Executive Officer168,663Aug 4, 20261
Perrin StevenPresident81,215Aug 4, 20261
Katkin KeithDirector8,575Jan 16, 20261
McBride John S.Director3,430Jan 16, 20261
Lee JuneDirector3,430Jan 16, 20261
Robinson James A. Jr.Director3,430Jan 16, 20261
Hillson JanDirector3,430Jan 16, 20261
Kirk AllanDirector3,430Jan 16, 20261
Smith Bryan E.General Counsel, Corporate Sec–Jan 13, 20250
Little Paul SeanChief Financial Officer–Jan 13, 20250
Biotechnology Value Fund L POther: See Explanation of Responses220,460Oct 31, 20240
BVF Partners L P10% Owner220,460Oct 31, 20240
BVF Inc10% Owner220,460Oct 31, 20240
Biotechnology Value Fund II LPOther: See Explanation of Responses220,460Oct 31, 20240
Lampert Mark N10% Owner220,460Oct 31, 20240
Biotechnology Value Trading Fund OS LPOther: See Explanation of Responses220,460Oct 31, 20240
BVF Partners OS Ltd.Other: See Explanation of Responses220,460Oct 31, 20240
BVF I GP LLCOther: See Explanation of Responses220,460Oct 31, 20240
BVF II GP LLCOther: See Explanation of Responses220,460Oct 31, 20240
BVF GP Holdings LLC10% Owner220,460Oct 31, 20240
Lyons Gary ADirector–May 2, 20230
Ogier Walter CDirector–May 2, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 31, 2024 (view filing)5:52 PM ETOct 292 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Stock, $0.001 par value+4.75M$3.65+$17.3M–838.5K afterDerivative3 lots
May 13, 2024 (view filing)5:04 PM ETMay 94 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Stock, $0.001 par value+1.93M––New position220.5K after3 lots
May 13, 2024 (view filing)5:04 PM ETMay 94 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Stock, $0.001 par value+5.93M–––232.1K afterDerivative3 lots
May 9, 2023 (view filing)8:25 PM ETMay 54 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Stock, $0.001 par value+1.98M––New position145.0K after3 lots
May 9, 2023 (view filing)8:25 PM ETMay 54 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchaseCommon Stock, $0.001 par value+9.59M–––252.3K afterDerivative6 lots
Nov 23, 2022 (view filing)Nov 23Same dayPerrin StevenPresidentPPurchase+1.00K$2.60+$2.60KNew position1.00K after
Dec 21, 2021 (view filing)Dec 201 dayGros David-Alexandre CChief Executive OfficerPPurchase+2.00K$4.48+$8.96K+28.6%9.00K after
Aug 19, 2021 (view filing)Aug 172 daysGros David-Alexandre CChief Executive OfficerPPurchase+4.00K$6.21+$24.8K+133.3%7.00K after